
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): September 14, 2010

STEREOTAXIS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-50884

(Commission
File Number)

94-3120386

(IRS Employer
Identification No.)

4320 Forest Park Avenue, Suite 100, St. Louis, Missouri
(Address of Principal Executive Offices)

63108
(Zip Code)

(314) 678-6100

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. Regulation FD Disclosure.

On September 14, 2010, Stereotaxis, Inc. (the “Company”) issued a press release (the “Press Release”) announcing that executive management will present at the CL King 8th Annual Best Ideas Conference to be held September 15-16, 2010 at the Omni Berkshire Place Hotel in New York City and the Stifel Nicolaus Healthcare Conference to be held September 15-17, 2010 at the Four Seasons Hotel in Boston. The Press Release is attached hereto as Exhibit 99.1.

The audio web cast of the presentation, and the investor presentation are available online on the Investor Relations portion of the Company’s website at at <http://www.stereotaxis.com/Investor-Relations>. The slides are attached hereto as Exhibit 99.2.

The Press Release and the presentation slides are being furnished pursuant to Item 7.01, and the information contained therein shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

The presentation slides that are attached to this Current Report on Form 8-K as Exhibit 99.2 include statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release dated September 14, 2010.

99.2 Stereotaxis, Inc. presentation slides for conferences to be held on September 15-17

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STEREOTAXIS, INC.

Date: September 14, 2010

By: /s/ Daniel J. Johnston

Name: Daniel J. Johnston

Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.

Document

99.1	Press release dated September 14, 2010.
99.2	Stereotaxis, Inc. Presentation Slides for conferences to be held on September 15-17



Company Contact:
 Dan Johnston
 Chief Financial Officer
 314-678-6007

Investor Contact:
 EVC Group, Inc.
 Douglas Sherk & Greg Gin
 415-896-6820

Media Contact:
 EVC Group, Inc.
 Steve DiMattia
 646-201-5445

**Stereotaxis to Present at the CL King Best Ideas Conference and the Stifel Nicolaus
 Healthcare Conference**

St. Louis, MO, September 14, 2010 —Stereotaxis, Inc. (NASDAQ: STXS) today announced that executive management will present at the following investor conferences:

- The CL King 8th Annual Best Ideas Conference to be held September 15-16, 2010 at the Omni Berkshire Place Hotel in New York City. Mr. Dan Johnston, Chief Financial Officer, is scheduled to review the Company's business strategy and recent corporate developments at 2:45 PM ET on Wednesday, September 15, 2010.
- The Stifel Nicolaus Healthcare Conference to be held September 15-17, 2010 at the Four Seasons Hotel in Boston. Mr. Johnston is scheduled to review the Company's business strategy and recent corporate developments at 10:20 AM ET on Thursday, September 16, 2010.

To listen to the audio web cast of the presentation during or after the event, or to view the investor presentation online, please visit: <http://www.stereotaxis.com/Investor-Relations>. The replay for the CL King presentation will be available for ninety days after the event. The replay for the Stifel Nicolaus presentation will be available for thirty days after the event.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The unparalleled clinical capability of Stereotaxis has driven more than 130 hospitals to adopt magnetic navigation for a growing number of complex ablation cases in all four chambers of the heart. Stereotaxis technology is now installed and used by 9 out of the Top 10 Best U.S. Heart Hospitals as ranked by U.S. News and World Report, and more than one third of the EP academic training

centers in the United States have included Stereotaxis into their arrhythmia treatment laboratories. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

About Odyssey

The Odyssey portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information around the world. Odyssey Vision standardizes data integration for magnetic and standard interventional labs by enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Through its proprietary data compression technology, Cinema enables sharing of live and recorded procedure data via a laptop anywhere over a secure high speed Internet connection. Hospitals can also share procedures with other institutions using Odyssey Network Connect providing a global forum for defining clinical best practices across a broad spectrum of medical procedures.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.



STEREOTAXIS

NASDAQ: STXS

Forward-Looking Statements

During the course of this presentation, the Company may make projections and other forward-looking statements regarding future events or the future financial performance of the Company, including without limitation, statements regarding future operating results, growth opportunities and other statements that refer to Stereotaxis' plans, prospects, expectations, strategies, intentions and beliefs. These statements are subject to many risks and uncertainties that could cause actual results to differ materially from expectations.

For a detailed discussion of risk and uncertainties that affect the Company's business and qualify the forward-looking statements made in this presentation, we refer you to the Company's recent public filings filed with the SEC, specifically the Form 10-K for the fiscal year ended December 31, 2009.

The Company's projections and forward-looking statements are based on factors that are subject to change and therefore these statements speak only as of the date they are given. The Company assumes no obligation to update any projections or forward-looking statements.

In addition, regarding orders and backlog, there can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period, or at all, because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. These orders and commitments may be revised, modified, or canceled either by their express terms, as a result of negotiations, or by project changes or delays.




Investment Considerations

- Addressing market opportunity through two distinct platforms:
 - Magnetic Navigation (Niobe)
 - Enterprise Solutions (Odyssey)
- Large, high growth (+20%) cardiology ablation market
- Commercial ramp began in mid 2008; leading peer group grower in 2009 through strong fundamentals
- Poised for continued growth in EP
- Long term platform expansion into new markets





Stereotaxis Magnetic Platform

Stereotaxis steers the catheter's distal tip through external magnetic fields thus giving the physician precise remote control of therapeutic devices.



Stereotaxic Value - Magnetic Platform

- ▶ Precise control of the distal tip of the catheter results in:
 - ▶ Exemplary safety
 - ▶ Effective lesion creation through constant contact
 - ▶ Exceptional mapping capability
- ▶ Proven in all chambers of the heart



Clinical Environment Overview Market

Before Stereotaxis



After Stereotaxis



Physician

In procedure room

In control room

Safety

Physician: significant X-ray exposure
Patient: major event rate ~2.8%

Almost no X-ray exposure

Major event rate reduced to 0.1%

Efficacy

High re-do rates

Several applications clearly better than manual
- VT, pediatrics, congenital heart diseases
Other applications comparable to manual

Efficiency

Wide standard deviation based on patient and physician

Standardized process drives tighter distribution around procedure times



Global EP Market

	<u>EP Procedures</u>	<u>Prevalence</u>	<u>Annual Procedures</u>	<u>Annual Growth</u>
	Routine	+20M	170k	<10%
Our Focus	AF	+10M	100k	25%
	VT	+3M	30k	15%
	Other	+5M	40k	15%
	Total Complex	+18M	170k	20%

Source: Millennium Research Group (2009); Stereotaxis internal analysis


Strong Clinical Validation

More than 150 Peer-Reviewed Publications



Radiation Reduction


Patients – 67%¹
Physicians – 90%²




1. Haghjoo, JCE 2009. 2. Latcu, Arch Cardiovasc Dis 2009. 3. Schwagten, PACE 2009. 4. DiBiase, JCE 2009.
5. Augello, Heart Rhythm 2009. 6. Schwagten, PACE 2009. 7. Haghjoo, JCE 2009. 8. DiBiase, Heart Rhythm 2009.

VT Comparison Study Erasmus MC

- 64 consecutive VT ablation patients
 - 37 Stereotaxis
 - 27 manual
 - Idiopathic & Scar-Related
- No complications in Stereotaxis group
- 1 tamponade/death in manual group
- Conclusion: “Major clinical & cost advantages for VT ablation”




Odyssey EnterpriseTM Solutions



Odyssey Vision



The Odyssey Product Line




Business Model

Capital Revenue

Niobe



Odyssey Workstation



Odyssey Cinema



Recurring Revenue

Equipment service

- Technical service
- Software license
- 1-year warranty

Niobe Utilization

- Stereotaxis disposables
- Royalty from J&J BWI

- 141 Niobe systems installed
- 2,500 EP labs worldwide
- 20+% growth; ~60% margin

- 25% growth (YTD 2010 vs. 2009)
- 80% margin

27% growth (2009 vs. 2008); 65+% margin



Market Adoption & Procedure Growth


Growing Worldwide Penetration

141 Systems Installed



Cumulative Procedures

30,000 + procedures




60% US - 40% OUS



Stereotax Financial Update


\$ millions

New Orders to Backlog



\$ millions

Recurring Revenue




\$ millions

Revenue Momentum




Stereotax Financial Update

Gross Margin Percentage




\$ millions

Operating Expenses




\$ millions

Total Inventory




\$ millions

Cash Flow (Burn)



Liquidity

\$ Millions



* Cash burn includes repayment of Biosense Webster advance.

Q2 2010 Cash Burn Analysis

\$ Millions



2010 Focus

I. Drive Commercial Success

	<u>Metrics</u>
Clinical training/process accelerates adoption	25% growth recurring revenue*
Adoption creates stronger reference sites	5 → 17
Reference sites accelerate capital pipeline & sales	Q2 2010 orders doubled over 2009
Niobe orders generate Odyssey opportunities	Odyssey revenue up 164%*
Odyssey (robotic labs) placements generate standard lab interest	Standard lab sales 36% of total Odyssey*

II. Strengthen EP Product Offering

Product extensions Odyssey link, Interface, Carto III
New capabilities launched with VDrive™



* Year to Date 2010

Q & A

